Pfizer Inc. logo

Pfizer Inc. (0Q1N)

Market Closed
10 Dec, 15:30
LSE LSE
$
25. 57
-0
-0%
$
- Market Cap
14.55 P/E Ratio
1.68% Div Yield
68,756 Volume
1.43 Eps
$ 25.57
Previous Close
Day Range
25.25 25.62
Year Range
20.77 27.85
Want to track 0Q1N and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 51 days

Summary

0Q1N closed Wednesday lower at $25.57, a decrease of 0% from Tuesday's close, completing a monthly increase of 3.43% or $0.85. Over the past 12 months, 0Q1N stock lost -4.29%.
0Q1N pays dividends to its shareholders, with the most recent payment made on Dec 01, 2025. The next estimated payment will be in In 2 months on Mar 01, 2026 for a total of $0.43.
The last earnings report, released on Nov 04, 2025, missed the consensus estimates by -0.02%. On average, the company has fell short of earnings expectations by -0.01%, based on the last three reports. The next scheduled earnings report is due on Feb 02, 2026.
Pfizer Inc. has completed 6 stock splits, with the recent split occurring on Nov 17, 2020.
The company's stock is traded on 17 different exchanges and in various currencies, with the primary listing on NYSE (USD).

0Q1N Chart

Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider

Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.

Zacks | 2 days ago
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.

Reuters | 2 days ago
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence

PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.

Zacks | 2 days ago

Pfizer Inc. (0Q1N) FAQ

What is the stock price today?

The current price is $25.57.

On which exchange is it traded?

Pfizer Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is 0Q1N.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.68%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Feb 02, 2026.

Has Pfizer Inc. ever had a stock split?

Pfizer Inc. had 6 splits and the recent split was on Nov 17, 2020.

Pfizer Inc. Profile

Pharmaceuticals Industry
Healthcare Sector
Albert Bourla CEO
LSE Exchange
US7170811035 ISIN
US Country
81,000 Employees
7 Nov 2025 Last Dividend
17 Nov 2020 Last Split
13 Aug 2012 IPO Date

Overview

Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.

Products and Services

  • Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands: Targeting cardiovascular metabolic, migraine, and women's health, these products offer innovative treatments in their respective therapeutic areas.
  • Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands: Focused on infectious diseases with unmet medical needs, including vaccines for various age groups and conditions.
  • Comirnaty and Paxlovid brands: At the forefront of COVID-19 prevention and treatment, offering some of the earliest and most effective vaccines and antiviral treatments against the virus. Furthermore, Pfizer is exploring potential future mRNA and antiviral products.
  • Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands: Offering biosimilars and original treatments for chronic immune and inflammatory diseases, showing Pfizer’s commitment to broadening access to critical medication.
  • Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands: Addressing rare and severe conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease with cutting-edge biopharmaceutical treatments.
  • Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands: Including sterile injectable and anti-infective medicines that play a vital role in treating various infections and conditions.
  • Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands: A comprehensive list of biologics, small molecules, immunotherapies, and biosimilars for treating cancer and other severe diseases, showcasing Pfizer’s extensive contribution to oncology and other advanced therapeutic areas.
  • Contract Manufacturing: In addition to its extensive pharmaceutical product lineup, Pfizer is also involved in the contract manufacturing business, leveraging its vast infrastructure and expertise to produce medicines for other entities.

Contact Information

Address: 235 East 42nd Street
Phone: 212 733 2323